Lee's Pharmaceutical Holdings Limited
0950.HKHKSEHealthcareMedical - Pharmaceuticals
Latest quote
HK$1.135
−HK$0.005 · -0.44%
0950.HK company overview
Regular session · HKT · Market data may be delayed.
Company profile
Company websiteLee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- Headquarters
- HK
- CEO
- Wanee Leelalertsuphakun
- Listed since
- Jul 15, 2002
- Employees
- 1,094
Market position
Day range
Current HK$1.135
52-week range
Current HK$1.135
- Open
- HK$1.14
- Previous close
- HK$1.14
- Volume
- 145K
- 0.22× average
- Average volume
- 672.75K
- Average daily volume
- Market cap
- 668.33M HKD
- Beta
- 0.57
- Market reference 1
- 50-day average
- HK$1.0879
- +4.33% above average
- 200-day average
- HK$1.3312
- -14.74% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 855.6M HKD
- P/E (TTM)
- 7.28×
- P/B (TTM)
- 0.33×
- P/S (TTM)
- 0.47×
- EV / EBITDA
- 4.32×
- Earnings yield
- 10.27%
- Free cash flow yield
- 11.32%
- Dividend yield
- 3.96%
Profitability & efficiency
- Gross margin
- 50.81%
- Operating margin
- 5.99%
- Net margin
- 6.40%
- Return on equity
- 4.49%
- Return on assets
- 2.65%
- Return on invested capital
- 2.33%
Financial health
- Debt / equity
- 0.15×
- Current ratio
- 1.03×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (HKD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.44B HKD | 1.4B HKD | 1.05B HKD | 1.23B HKD | 1.27B HKD |
| Cost of goods sold | 706.42M HKD | 646.61M HKD | 501.72M HKD | 462.39M HKD | 459.87M HKD |
| Gross profit | 729.56M HKD | 753.36M HKD | 551.31M HKD | 770.76M HKD | 806.28M HKD |
| Research and development | 169.02M HKD | 83.83M HKD | 96.8M HKD | 168.89M HKD | 243.84M HKD |
| Selling, general, and administrative | 557.12M HKD | 596.29M HKD | 494.19M HKD | 544.88M HKD | 663.7M HKD |
| Operating expenses | 643.6M HKD | 640.21M HKD | 507.76M HKD | 694.49M HKD | 997.82M HKD |
| Interest income | 1.78M HKD | 1.77M HKD | 1.53M HKD | 2.39M HKD | 5.91M HKD |
| Interest expense | 11.23M HKD | 13.82M HKD | 11.9M HKD | 7.6M HKD | 5.72M HKD |
| Depreciation and amortization | 87.76M HKD | 147.73M HKD | 149.5M HKD | 152.5M HKD | 146.87M HKD |
| Operating income | 85.96M HKD | 113.14M HKD | 43.55M HKD | 76.56M HKD | 1.98B HKD |
| Net income | 91.94M HKD | 93.1M HKD | 16.7M HKD | 51.28M HKD | 1.99B HKD |
Company facts updated Aug 24, 2026.
Earnings
- Latest EPS result
- 0.11
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
HK$0.047
2025 complete year-23.0% since 2021
2026 partial: HK$0.023
HK$0.061
2,021
HK$0.041
2,022
HK$0.018
2,023
HK$0.03
2,024
HK$0.047
2,025
HK$0.023
2,026*
* Partial calendar year in the available dividend history.
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | May 27, 2026 | HK$0.023Semi-Annual | May 28, 2026 | Jun 15, 2026 |
Dividend | Sep 12, 2025 | HK$0.022Semi-Annual | Sep 15, 2025 | Oct 3, 2025 |
Dividend | May 28, 2025 | HK$0.025Semi-Annual | May 30, 2025 | Jun 16, 2025 |
Dividend | Sep 12, 2024 | HK$0.02Semi-Annual | Sep 13, 2024 | Oct 3, 2024 |
Dividend | May 28, 2024 | HK$0.01Semi-Annual | May 29, 2024 | Jun 17, 2024 |
Dividend | Sep 12, 2023 | HK$0.008Semi-Annual | Sep 13, 2023 | Oct 4, 2023 |
Ex-dividend May 27, 2026
HK$0.023
Semi-Annual
Record May 28, 2026 · Payment Jun 15, 2026
Ex-dividend Sep 12, 2025
HK$0.022
Semi-Annual
Record Sep 15, 2025 · Payment Oct 3, 2025
Ex-dividend May 28, 2025
HK$0.025
Semi-Annual
Record May 30, 2025 · Payment Jun 16, 2025
Ex-dividend Sep 12, 2024
HK$0.02
Semi-Annual
Record Sep 13, 2024 · Payment Oct 3, 2024
Ex-dividend May 28, 2024
HK$0.01
Semi-Annual
Record May 29, 2024 · Payment Jun 17, 2024
Ex-dividend Sep 12, 2023
HK$0.008
Semi-Annual
Record Sep 13, 2023 · Payment Oct 4, 2023
0950.HK peers
ETFs holding 0950.HK
Funds reporting this stock among their holdings, ordered by reported position size.
Avantis Emerging Markets Equity ETFAVEM100.19K—27.89B USD0.33%$94.24+0.75%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM67.32K0.00%9.49B USD0.39%$39.93+0.50%
Dimensional World ex U.S. Core Equity 2 ETFDFAX34.61K0.00%12.57B USD0.28%$38.16+0.82%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE290.810.00%638.17M USD0.44%$48.59+0.65%Avantis Emerging Markets Equity ETFAVEM- Market value
- 100.19K
- Weight
- —
- AUM
- 27.89B USD
- Expense ratio
- 0.33%
- Price / 1D
- $94.24+0.75%
Dimensional - Emerging Markets Core Equity 2 ETFDFEM- Market value
- 67.32K
- Weight
- 0.00%
- AUM
- 9.49B USD
- Expense ratio
- 0.39%
- Price / 1D
- $39.93+0.50%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 34.61K
- Weight
- 0.00%
- AUM
- 12.57B USD
- Expense ratio
- 0.28%
- Price / 1D
- $38.16+0.82%
Dimensional Emerging Markets Sustainability Core 1 ETFDFSE- Market value
- 290.81
- Weight
- 0.00%
- AUM
- 638.17M USD
- Expense ratio
- 0.44%
- Price / 1D
- $48.59+0.65%
Continue in GoAI
Research 0950.HKresearch.disclaimer